Subclinical hypercortisolism: a state, a syndrome, or a disease?

Guido Di Dalmazi, Renato Pasquali1, Felix Beuschlein and Martin Reincke

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ziemssenstrasse 1, D-80336 München, Germany and 1Endocrinology Unit, Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, Alma Mater University of Bologna, 40138 Bologna, Italy

Abstract

Subclinical hypercortisolism (SH), defined as alterations of the hypothalamus-pituitary-adrenal axis in the absence of clinical signs or symptoms related to cortisol secretion, is a common finding in patients with adrenal incidentalomas. The clinical correlates of this pathological condition have become clearer over the last few years. The aim of this review is to summarize the co-morbidities and the clinical outcomes of patients with SH. According to the analysis of the results of the studies published within the last 15 years, hypertension and type 2 diabetes are a common finding in patients with SH, occurring roughly in 2/3 and 1/3 of the patients respectively. Moreover, several additional cardiovascular and metabolic complications, like endothelial damage, increased visceral fat accumulation and impaired lipid metabolism have been shown to increase the cardiovascular risk of those patients. Accordingly, recent independent reports investigating the natural history of the disease in a long-term follow-up setting have shown that patients with SH have a higher incidence of cardiovascular events and related mortality. Moreover, longitudinal studies have also shown increased incidence of osteoporotic vertebral fractures. Future research is needed to improve the diagnostic performance of hormonal tests, by assessment of the complete steroid profile with more accurate assays, and to define the efficacy of surgical vs medical treatment in a randomized-controlled setting.

Introduction

The term ‘adrenal incidentaloma’ was coined to identify a group of adrenal masses that are incidentally discovered during imaging techniques performed for disorders unrelated to the adrenal gland. Despite the majority of those tumors are benign and not associated with clinically-relevant hormonal hyperfunction (namely cortisol, aldosterone, and catecholamines), an increasing number of patients with mild alteration of cortisol secretion without phenotype of Cushing’s syndrome has been identified over the last decades. In an attempt to classify this subset of patients in a homogeneous group, the terms ‘subclinical (or pre-clinical) Cushing’s syndrome’, ‘subclinical autonomous glucocorticoid hypersecretion’ and ‘subclinical hypercortisolism (SH)’ has been variably used...
in several publications. The term ‘SH’ will be followed in this review because it is widely used in the most recent literature and it is the most appropriate description in our opinion. SH is becoming a very common finding in patients with adrenal incidentalomas (1, 2) and it recently has been a matter of intensive research. However, no clear and homogeneous indications for the diagnosis of these patients are available, leading to difficulty in the definition of a clinical phenotype and uncertainty in the appropriate post-diagnostic procedures (management and follow-up).

The aim of this review is to summarize the published evidence on co-morbidities and clinically relevant outcomes associated with SH, in order to depict a clinical picture of patients affected by this condition.

Remarks on diagnosis

An extensive review on the diagnosis of SH has already been published in recent years (3) and is beyond the scope of this review. However, considering that diagnosis is a central aspect when dealing with SH, some important remarks regarding radiological, clinical and hormonal characteristics of this pathological condition will be discussed below.

The classical triad commonly used to define SH is characterized by the presence of alterations of the hypothalamic–pituitary–adrenal axis in patients with incidentally discovered adrenal masses who do not exhibit signs and symptoms specific of overt Cushing’s syndrome. This apparently simple definition carries several drawbacks that must be dealt with by physicians who face an increasing number of patients diagnosed with adrenal incidentalomas.

Radiological evaluation

By definition, adrenal incidentalomas are diagnosed with an imaging technique, such as ultrasonography, computerized tomography (CT), or magnetic resonance imaging, performed for reasons unrelated to adrenal diseases. Although imaging techniques are extremely helpful in the definition of the nature of adrenal incidentalomas (4, 5, 6), there is not enough evidence that they can be used to characterize the functional status of the adenomas. In fact, only one study recently published by Olsen et al. (7) tried to investigate this possibility. In their cohort of 146 patients with complete hormonal evaluation, SH was defined using a combination of cortisol values after dexamethasone suppression test (DST) above 1.8 μg/dl and basal adrenocorticotropic hormone (ACTH) levels below 10 pg/ml. The group of unilateral adrenal masses with size over 2.5 cm and CT attenuation below 1 showed a 45% prevalence of SH. Coherently, the probability of having SH correlated positively with the size and negatively with the density of the adrenal mass. Although this study carries several limitations due to its multicentric design and incomplete hormonal data in around 1/3 of the patients, it highlights that the radiological characteristics can be useful in distinguish the nature, as already known, but also the functional status of the adrenal mass.

However, even if the radiological definition of the adrenal incidentalomas has become clearer in recent years due to the development of highly advanced techniques including functional imaging and to the increasing skill of radiologists (who are chiefly dedicated to endocrine diseases in some centers), no single or combined radiological parameters can be helpful in assessing the functional status of the adrenal mass.

Clinical evaluation

The first difficulty in the diagnosis of SH has to do with the recognition of the phenotypical aspect of the patients. By definition, physicians should suspect this condition in patients without typical signs and symptoms of Cushing’s syndrome. However, it is well known from daily clinical practice that recognition of Cushing’s syndrome and its differential diagnosis with obesity, especially the sarcopenic phenotype (8), can be extremely challenging. This aspect has been beautifully highlighted by Schneider et al. (9) in 2012, showing that the clinical picture of Cushing’s syndrome has changed during the last 20 years, mainly because of the increasing knowledge among physicians about the clinical phenotype of hypercortisolism, which allows early recognition of the disease. It must be pointed out that the increasing ability to recognize patients with Cushing’s syndrome could vary greatly among different centers, especially considering that there are some centers more prone than others to assist patients with adrenal diseases.

In this context, it must be emphasized that the absence of clinical signs and symptoms related to cortisol hypersecretion, which is the first rate-limiting step in the definition of SH, is a very weak diagnostic criterion because it relies entirely on the clinical evaluation of single physicians and therefore on their personal experience. However, as discussed later in this review, evidence from recent studies highlights the fact that associated clinical biomarkers (e.g., increased visceral fat accumulation) and specific co-morbidities can contribute to define a characteristic clinical picture in patients with SH.
Hormonal evaluation

Hormonal parameters to define SH are an additional source of uncertainty. To date, there are five clinical practice guidelines available (10, 11, 12, 13, 14), which have been critically reviewed by Shen et al. (15) in 2014. In their quality assessment, the authors revealed that the guidelines of the Endocrine Society and those of the Italian Association of Medical Endocrinologists (AME) are the most recommendable among the others, albeit with modifications, according to the criteria of the Appraisal of Guidelines Research and Evaluation (AGREE-II) and those of the Institute Of Medicine (IOM) (15). All published guidelines agree with the use of 1 mg DST for the screening of hypercortisolism. However, there is disagreement on the best cut-off for cortisol after DST, since values of 1.8µg/dl as well as 5.0µg/dl are recommended as limits for normal cortisol suppression. The landscape of the different cut-offs for cortisol after DST is even more complex when calculated as mean ±2 S.D. values obtained from 72 control subjects without adrenal masses at high-resolution CT scan, could be even lower than 50 nmol/l, as it was set to 30.1 nmol/l. In addition, several different complementary criteria have been proposed by the guidelines as adjunctive diagnostic test in order to improve the sensitivity and the specificity in the detection of SH. The accuracy of the most frequently used hormonal tests has been already assessed in a comprehensive review published by Chiodini (3) in 2011. According to the results of this analysis, it is clear that the main source of variability in sensitivity and specificity relies on the outcomes that were used to calculate those two parameters. Overall, ACTH and urinary free cortisol (UFC) did not show satisfactory sensitivity and specificity in detecting SH, whereas the altered circadian rhythm of cortisol, measured by increased midnight cortisol either in saliva or in serum, showed a reasonable accuracy (sensitivity 64%, specificity 81%) in predicting post-surgical hypocortisolism (considered as an indirect index of adrenal autonomy). An even higher variability in sensitivity and specificity was observed for cortisol after DST, when different cut-offs were set (3). It is clear that the lowest cut-off (1.8 µg/dl) leads to high sensitivity, which, in turn, decreases with the highest cut-off point (5 µg/dl). The opposite trend is observed for specificity, as expected. In order to overcome this problem, the AME has proposed the use of a double cut-off for cortisol (1.8 and 5 µg/dl) (14) that could be indeed a good compromise to achieve the highest diagnostic performance of the DST. In this view, hormonal tests with lower predictive accuracy (ACTH, UFC, or midnight cortisol) can be used as additional tests in cases of intermediate values of cortisol after DST (between 1.8 and 5 µg/dl). Overall, the DST is the most reliable test to separate patients in different groups according to the severity of hypercortisolism, providing useful information to define patients at high risk of developing severe outcomes (as discussed in the next sections of this review).

However, the diagnostic flow-chart of SH is highly challenging and clear standards are still lacking. The most obvious consequence of this uncertainty is the non-homogeneous classification of the patients among different centers that invariably lead to non-reproducible results in the analysis of clinical correlates. Therefore, the diagnostic criteria used to define patients with SH must be always taken into account when interpreting the results of studies that could affect the management of these patients in clinical practice. Future research is needed to assess the response of cortisol after DST, together with a daily rhythm of salivary cortisol, in a large cohort of normal subjects without proven morphological alterations in the adrenal glands, in order to create standardized cut-offs and definitely lower the variability among studies.

Overview of associated co-morbidities

It is a well-established concept that hypercortisolism can lead to associated co-morbidities, including metabolic and cardiovascular disturbances, as known from patients with overt Cushing’s syndrome. SH has been associated with several metabolic and cardiovascular co-morbidities (18), even if there are contrasting results in the literature published up to now. However, the most common metabolic and cardiovascular correlates reported in patients with this condition are hypertension and impairment of glucose metabolism, mainly type 2 diabetes (T2D), which will be briefly discussed below. Table 1 shows an overview of the studies published in the last 15 years with data on prevalence of hypertension and T2D in cohorts with at least ten patients with SH. Accurate calculation of the total mean prevalence of hypertensive and diabetic patients among studies would lead to non-realistic results, due to an overlap between several cohorts of patients, which are difficult to identify.
Hypertension is one of the most common clinical features of patients with SH. The link between hypercortisolism and hypertension is well known in patients with endogenous and iatrogenic Cushing’s syndrome, despite the exact mechanisms of the glucocorticoid-induced hypertension being still under investigation. Hypertension in Cushing’s syndrome could be explained by a concurrence of several events, such as an impaired imbalance between vasodilators and vasoconstrictors (e.g., nitric oxide, prostacyclin, and endothelin-1) and activation of the mineralocorticoid receptor (19, 20, 21, 22, 22). Moreover, several endothelial abnormalities and left ventricular dysfunctions have also been recorded (21, 22), indirectly confirming that the degree of hypertension in those patients could be indeed severe. The involvement of cortisol has been indirectly demonstrated by the positive effects of adrenalectomy on the cardiovascular profile of patients with SH. In a very recent systematic review of the literature published over the last 33 years, Iacobone et al. (23) showed that the surgical treatment appears to be more beneficial than medical therapy in achieving a cure or improvement of hypertension. Despite not being completely understood, the link between SH and hypertension can rely on direct effects of cortisol on the vascular system, as well as on indirect mechanisms, through impairment of glucose metabolism and increased waist circumference (as discussed below).

SH has been associated with impaired glucose metabolism, ranging from insulin resistance to T2D. Two recent reports showed increasing degrees of alterations of indices of insulin resistance in controls, patients with non-functioning adrenal adenomas and SH (24, 25). T2D occurs in roughly one third of patients with SH. However, as expected, there is a high variability between studies, with prevalence of T2D that range from 5% to 69%, which could be explained by several factors, such as the different

<table>
<thead>
<tr>
<th>References</th>
<th>Total cohort (n)</th>
<th>Patients with SH (n)</th>
<th>Hypertension (%) SH</th>
<th>Hypertension (%) NF/controls</th>
<th>Type 2 diabetes (%) SH</th>
<th>Type 2 diabetes (%) NF/controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>(51)</td>
<td>50</td>
<td>12</td>
<td>92</td>
<td>–</td>
<td>42</td>
<td>–</td>
</tr>
<tr>
<td>(1)</td>
<td>1004</td>
<td>92</td>
<td>41</td>
<td>–</td>
<td>8</td>
<td>–</td>
</tr>
<tr>
<td>(44)</td>
<td>126</td>
<td>28</td>
<td>61</td>
<td>–</td>
<td>36</td>
<td>–</td>
</tr>
<tr>
<td>(52)</td>
<td>167</td>
<td>23</td>
<td>35</td>
<td>53</td>
<td>14</td>
<td>26</td>
</tr>
<tr>
<td>(53)</td>
<td>11</td>
<td>11</td>
<td>63</td>
<td>–</td>
<td>36</td>
<td>–</td>
</tr>
<tr>
<td>(54)</td>
<td>103</td>
<td>22</td>
<td>50</td>
<td>58</td>
<td>27</td>
<td>16</td>
</tr>
<tr>
<td>(55)</td>
<td>45</td>
<td>45</td>
<td>73</td>
<td>–</td>
<td>31</td>
<td>–</td>
</tr>
<tr>
<td>(56)</td>
<td>77</td>
<td>20</td>
<td>75</td>
<td>56</td>
<td>20</td>
<td>23</td>
</tr>
<tr>
<td>(57)</td>
<td>108</td>
<td>41</td>
<td>59</td>
<td>57</td>
<td>27</td>
<td>9</td>
</tr>
<tr>
<td>(58)</td>
<td>118</td>
<td>16</td>
<td>81</td>
<td>58</td>
<td>19</td>
<td>15</td>
</tr>
<tr>
<td>(59)</td>
<td>60</td>
<td>29</td>
<td>48</td>
<td>61</td>
<td>35</td>
<td>13</td>
</tr>
<tr>
<td>(60)</td>
<td>63</td>
<td>63</td>
<td>79</td>
<td>–</td>
<td>16</td>
<td>–</td>
</tr>
<tr>
<td>(61)</td>
<td>16</td>
<td>16</td>
<td>56</td>
<td>–</td>
<td>25</td>
<td>–</td>
</tr>
<tr>
<td>(36)</td>
<td>348</td>
<td>145b</td>
<td>82</td>
<td>73</td>
<td>27</td>
<td>15</td>
</tr>
<tr>
<td>(62)</td>
<td>35</td>
<td>35</td>
<td>77</td>
<td>–</td>
<td>46c</td>
<td>–</td>
</tr>
<tr>
<td>(7)</td>
<td>146</td>
<td>40</td>
<td>83</td>
<td>65</td>
<td>11d</td>
<td>8d</td>
</tr>
<tr>
<td>(63)</td>
<td>213</td>
<td>51</td>
<td>65</td>
<td>55</td>
<td>26</td>
<td>24</td>
</tr>
<tr>
<td>(64)</td>
<td>29</td>
<td>29</td>
<td>57</td>
<td>–</td>
<td>41</td>
<td>–</td>
</tr>
<tr>
<td>(65)</td>
<td>70</td>
<td>16</td>
<td>69</td>
<td>59</td>
<td>69e</td>
<td>32e</td>
</tr>
<tr>
<td>(66)</td>
<td>298</td>
<td>66</td>
<td>71</td>
<td>61</td>
<td>27</td>
<td>21</td>
</tr>
<tr>
<td>(46)</td>
<td>206</td>
<td>39</td>
<td>67</td>
<td>54</td>
<td>33</td>
<td>17</td>
</tr>
<tr>
<td>(45)</td>
<td>198</td>
<td>69</td>
<td>65</td>
<td>57</td>
<td>30</td>
<td>14</td>
</tr>
<tr>
<td>(47)</td>
<td>206</td>
<td>111</td>
<td>64e</td>
<td>58e</td>
<td>24d</td>
<td>21d</td>
</tr>
<tr>
<td>(67)</td>
<td>27</td>
<td>27</td>
<td>59</td>
<td>–</td>
<td>37</td>
<td>–</td>
</tr>
<tr>
<td>(68)</td>
<td>237</td>
<td>19</td>
<td>78</td>
<td>55</td>
<td>42</td>
<td>29</td>
</tr>
<tr>
<td>(69)</td>
<td>33</td>
<td>33</td>
<td>73</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>(29)</td>
<td>330</td>
<td>93</td>
<td>74</td>
<td>62</td>
<td>41f</td>
<td>31f</td>
</tr>
</tbody>
</table>

SH, subclinical hypercortisolism; NF, non-functioning adrenal masses.

*Exact prevalence not reported, but not different respect to that of non-secreting adenomas (n=854).

*A total of 19 SH patients (cortisol after dexamethasone suppression test above 5 μg/dl) and 126 patients with intermediate phenotype (cortisol after dexamethasone suppression test between 1.8 and 5 μg/dl).

*Including impaired glucose tolerance.

*Percentage of patients on hypertensive treatment.

*Percentage of patients on antidiabetic treatment.
diagnostic criteria to define SH, the change in diagnosis of T2D over a 15-year time span and the numerosity of the samples in different studies. A pathogenetic role of cortisol in the development of impairment glucose metabolism is easy to assume, considering the well-known effects of glucocorticoids on gluconeogenesis, insulin-dependent uptake in peripheral tissues and secretory activity of pancreatic β-cells (26). However, subclinical cortisol hyperproduction can also lead to T2D through indirect mechanisms. It has been recently shown by Debono et al. (27) that patients with SH have a significantly higher visceral fat accumulation than patients with non-secreting adrenal masses, as measured by CT-scan. Interestingly, the increased visceral fat was not different from that of patients with Cushing’s syndrome. Moreover, recent studies have also pointed out that patients with SH have a high prevalence of nonalcoholic fatty liver disease and lipid metabolism alterations, which are independently associated with cortisol secretion (28, 29).

The presence of impaired glucose metabolism, visceral fat accumulation and lipid abnormalities concur to the dysmetabolic frame that is common in patients with SH. The involvement of cortisol in the development of metabolic abnormalities in SH has been indirectly demonstrated by studies investigating the concurrence of different risk factors with multifactorial analyses, but also by trials investigating the effects of adrenalectomy in ameliorating the metabolic abnormalities (23, 26). Nevertheless, despite it being able to play an independent and significant role, cortisol should be considered as an additional player in the set of factors potentially contributing to the development of metabolic alterations. Beside age and being overweight or obese, other important contributors should be taken into account, such as family history of T2D, physical activity and quantity and quality of daily food intake, the effects of all of which are frequently underestimated in studies analyzing patients with SH. Finally, the different duration of cortisol exposure must be also considered. As discussed in the next chapter of this review, retrospective studies analyzing the natural history of this pathological condition have highlighted that the time of exposure to mild cortisol hyperproduction could be an important factor for the development of cardiovascular and metabolic co-morbidities in patients with SH.

**SH and clinically-relevant outcomes**

The association between SH and clinically relevant outcomes has attracted the interest of several research groups, and increasing knowledge on this topic has been gained in the last few years. This section of the review will be focused on three clinical outcomes: osteoporotic fractures, cardiovascular diseases, and mortality.

**Osteoporotic fractures**

The deleterious effects of glucocorticoids on bone quality are well known from the analysis performed on patients with exogenous and endogenous hypercortisolism. Glucocorticoid-induced osteoporosis (GIO) is a complex disease characterized by increased bone resorption and decreased bone formation. One of the most frequent complications of GIO is the increased rate of vertebral fractures (30). In patients with overt Cushing’s syndrome, the reduced bone mineral density and the increased rate of osteoporotic fractures are a frequent complication of untreated hypercortisolism, independently of the underlying mechanism of increased cortisol production. However, several reports have highlighted that impairment of bone metabolism and its clinical consequences can also occur in conditions of mild cortisol excess. The relationship between SH and clinically relevant outcomes such as vertebral fractures has been intensively investigated over the last 10 years. Indeed, several studies highlighted an increased prevalence of osteoporotic fractures in patients with SH in comparison to those with non-functioning adrenal masses or control subjects (31, 32, 33, 34, 35, 36). Fractures were mainly observed in trabecular bone, as expected in GIO, at the level of thoracic spine. The multifactorial analysis performed in the studies cited above shed light on the association between hypercortisolism and alteration of bone microarchitecture (assessed by the spinal deformity index) and increased prevalence of vertebral fractures, which was independent of other known potential contributing factors (31, 32, 33, 34, 36). Interestingly, in the paper published by Tauchmanová et al. (32), the prevalence of vertebral fractures in SH was comparable to that of patients with overt Cushing’s syndrome.

Further interesting clues on this topic come from the first longitudinal study investigating the incidence of vertebral fractures in patients with SH. In their cohort of 103 patients followed-up for 2 years, Morelli et al. (35) demonstrated an increased incidence of vertebral fractures in patients with SH when compared to those with non-functioning adrenocortical adenomas (48% vs 13% respectively). The risk of developing new fractures was independently associated with the presence of SH (odds ratio (OR) 12.3, 95% CI 4.1–36.5, \( P = 0.001 \)), leading to the
hypothesis that the higher cortisol production rate detected in these patients could be indeed a causative factor for the increased vertebral fracture rate.

Except for the increased prevalence and incidence of vertebral fractures and the independent association of this outcome with cortisol, some aspects of these manuscripts deserve further reflection. Hypercortisolism has been shown to have the same deleterious effects on bone metabolism in both sexes, since it has previously demonstrated a similar prevalence of vertebral fractures in males (73% in ref. (33) and 69% in ref. (34)) and in females (76% in ref. (34) and 79% in ref. (31)). Therefore, SH seems to be a relevant problem for bone health independently of the sex of patients with adrenal incidentalomas. Another aspect that deserves further discussion is the relationship between cortisol, androgens and osteoporotic fractures. In their paper, Tauchmanová et al. (32) found an independent association between vertebral fractures and the cortisol/DHEAs ratio. The increased cortisol/DHEAs ratio is a well-known characteristic of patients with hypercortisolism and several hypotheses have been proposed to explain this peculiarity.

Molecular in vitro studies have shown that hyperfunctioning adrenocortical cells of adrenomas associated with Cushing’s syndrome have a low 17,20 lyase activity of the P450c17 enzyme due to a reduced expression of the co-factors cytochrome b5 and P450-oxidoreductase (37). P450c17 enzyme due to a reduced expression of the co-factors cytochrome b5 and P450-oxidoreductase (37). Moreover, reduction/suppression of ACTH driven by increased cortisol secretion by the adrenocortical adenoma can decrease the stimulation of the adjacent and contralateral adrenal cortex, resulting in low androgen production. The discovery of the inverse relationship between cortisol and DHEAs levels in hypercortisolism has also led to the proposal in the American guidelines to consider the reduced levels of DHEAs as a possible marker to identify SH (11, 13). Albeit the association between cortisol/DHEAs ratio and vertebral fractures could be due to the major effect of cortisol, it is not negligible that reduced DHEAs (and DHEA) levels could be an important contributing factor. In fact, several population-based longitudinal studies showed an association between DHEAs (and DHEA) and impairment of bone quality (38, 39). However, some reports have been inconclusive in finding any significant association between DHEAs levels and bone quality (40, 41). More data in support of the relationship between DHEA and bone quality come from randomized controlled trials showing that DHEA replacement therapy can improve significantly the bone mass density in post-menopausal women (42, 43). On the other hand, it must be specified that the beneficial effects of DHEA replacement in men were not always reproducible, and that the incidence of vertebral fractures has not been investigated in these studies. The exact mechanisms underlying the positive effects of DHEA on bone metabolism remain only speculative; increase in serum testosterone and insulin-like growth factor 1 has been proposed as potential causative factors.

In summary, patients with SH have an increased prevalence of osteoporotic fractures, but also a significant incidence of developing new fractures, which occur mainly in the thoracic spine. Hypercortisolism, even if mild, has been shown to be an important factor associated with the increased risk of developing such a clinically relevant outcome, acting through mechanisms that seem to be independent (and addictive) to the already known risk factors. The reduction in DHEAs and DHEA levels observed in SH could be also relevant in the impairment of bone quality, even if the contribution of these hormones to the genesis of osteoporotic fractures should be investigated in more detail.

Cardiovascular diseases

As discussed above, several reports on the co-morbidities associated with SH have led to the conclusion that the cardiovascular profile is indeed altered in those patients. However, the implications of the subclinical cortisol hypersecretion on the cardiovascular system, in terms of clinically relevant outcomes, have remained elusive until recently.

The first study investigating cardiovascular diseases in SH was published in 2002 (44). In their analysis of 28 patients with SH, Tauchmanová et al. (32) reported a 21% prevalence of symptomatic cardiovascular diseases and clinical evidence of cardiovascular profile impairment (symptoms of cardiopathy, obstructive vascular disease, carotid atherosclerotic plaques, or electrocardiogram abnormalities suggestive for heart function impairment) in 64% of the patients. However, no additional analyses were performed to assess the role of cortisol in the development of the impaired cardiovascular profile.

One of the first pieces of evidence for an association between SH and cardiovascular correlates came from a cross-sectional study published in 2012 (36). In this cohort of 348 patients with adrenal incidentalomas, patients were divided into four subgroups according to their secreting pattern. The progressively increased cortisol hypersecretion was identified by a double cut-off for cortisol levels after DST (below 1.8 mg/dl and above 5 mg/dl to identify non-secreting adrenomas and SH respectively) and by
additional hormonal parameters in patients with cortisol values between 1.8 and 5 µg/dl (defined as intermediate phenotype). A significant and progressive increase of prevalence of myocardial infarction was observed among groups (2.9% in non-secreting, 11.9% in patients with intermediate phenotype and 26.3% in SH), whereas the prevalence of stroke was not relevant, probably due to the low number of patients. The prevalence of coronary heart disease was associated with intermediate phenotype pattern (OR 4.1, 95% CI 1.5–11.4, P=0.007) and with SH (OR 6.1, 95% CI 1.4–26.5, P=0.016). Both patterns of secretion were associated with cardiovascular diseases independently of other known risk factors analyzed. Despite the limitations related to the cross-sectional design of the study, which do not allow any causative association, this study provided novel and interesting information that was later confirmed and extended in a subsequent longitudinal study published in 2014 (45). In this retrospective study, 198 patients with adrenal incidentalomas where classified as stable non-secreting and stable SH according to the cortisol levels after DST (with cut-off of 1.8 µg/dl) at the first and last evaluation. A subgroup of patients with increasing cortisol levels over time was also identified (worsening group). During a mean follow-up of 7.5±3.2 years, patients with SH and with worsening cortisol secretion showed a higher incidence of cardiovascular disease than those with non-secreting incidentalomas. The higher rate of cardiovascular events was associated with increasing levels of cortisol during follow-up (Hazard ratio (HR) 1.1, 95% CI 1.1–1.2, P=0.001) independent of other known risk factors. Additional interesting results come also from an Italian multicentric study, also published in the beginning of 2014 (46). In this retrospective cohort of 206 patients, SH was defined by cortisol levels after DST above 5 µg/dl, or by at least two hormonal impaired tests, including cortisol after DST above 3 µg/dl. During a long-term follow-up (median 6 years), Morelli and colleagues found a higher incidence of cardiovascular events in patients with SH than in those with non-secreting adenomas. The increased rate of cardiovascular events was associated with the presence of SH (OR 3.1, 95% CI 1.1–9.0, P<0.05). Similar results were also confirmed lately in a retrospective study published by Debono et al. (47) (discussed in detail in the next chapter of this review).

All together, these results highlight some important aspects. First of all, they provide good evidence for a central role of cortisol as a contributing factor to cardiovascular diseases. The deleterious effects of cortisol on the cardiovascular system are an established complication of Cushing’s syndrome (21, 22), leading to clinically relevant cardiovascular diseases. It is prudent to suspect that the same mechanisms occur also in patients with SH. Despite the specific mechanisms that lead to cardiovascular diseases in subclinical and overt hypercortisolism could share a common basis, it must be considered that this pathological condition is characterized by mild levels of cortisol that persist over a long period of time. Therefore, the impact of the duration of cortisol exposure of the cardiovascular system could be very important in patients with SH, albeit very difficult to demonstrate. The second aspect that deserves attention is that the increased cardiovascular disease rate also occurs in patients with progressive cortisol secretion, highlighting the importance and the necessity of a careful follow-up also in patients with non-secreting adrenocortical adenomas. However, it must be pointed out that not all patients with SH are at risk of developing cardiovascular diseases. The multifactorial analyses described above highlighted also the independent contribution of other factors besides cortisol that can be useful in drawing a picture of patients potentially at a higher risk for cardiovascular diseases (45). Undoubtedly, further research is needed in this field to try to characterize phenotypical and hormonal features that will help in identifying high-risk patients that could benefit either of surgical treatment, if feasible, or intensive medical therapy of co-morbidities, in order to restrict a careful and intensive follow-up only to patients at risk for clinically relevant outcomes.

Mortality

The analysis of mortality in patients with adrenal incidentalomas has firstly been described in two old studies, both performed in a long-term follow-up setting (mean 7 years) (48, 49). However, no hormonal assessment was addressed to identify patients with SH; therefore, it is difficult to draw definitive conclusions on mortality from the results of these reports. More consistent results were presented in one of the long-term follow-up studies previously cited (45). During a mean 7.5-years follow-up, patients with SH and with worsened secreting pattern showed a lower survival rate than that of patients with non-secreting adenomas, for all-cause mortality. A sub-analysis focused on the cardiovascular-specific mortality confirmed the same trend, with 78.4 and 60% survival rates for the first two groups respectively and 97.5% for the latter. Multifactorial analysis confirmed an independent role of cortisol levels after DST in the all-cause mortality (HR 1.1, 95% CI 1.1–1.2, P=0.04).
Debono et al. (47) also presented similar results in a retrospective study published at the end of 2014. In their cohort of 206 patients (mean follow-up 4.2 ± 2.3 years), patients with SH defined by cortisol levels after DST above 1.8 μg/dl showed an increased cardiovascular morbidity and mortality than in those with non-secreting adenomas. Interestingly, patients with adrenal incidentalomas showed an increased mortality rate due to cardiovascular diseases and infectious complications when compared to data extracted from the UK population.

Despite the inherent limitations due to the retrospective design and to the low number of deaths of the total cohort of patients, both studies highlight a possible link between SH and mortality of patients with adrenal incidentalomas. Considering that the main cause of mortality was due to cardiovascular diseases and infectious complication, it is feasible that the cortisol can play a significant role.

**Future perspectives**

Certainly, the pathological alterations described in this review do not apply to all patients with SH. Further research is therefore needed to identify a subpopulation of subjects at high risk of developing metabolic and cardiovascular abnormalities. In this context, the use of more accurate diagnostic procedures like steroid profiling analysis in blood and urine with gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/mass spectrometry (LC/MS) will have the potential to explore glucocorticoid, mineralocorticoid and androgen secretion in an extended quantitative and qualitative way. These innovative assays will have the potential to improve the classification of patients with adrenocortical masses by identifying steroid precursors potentially related to clinical correlates. As an important example of this application, a very recent paper published by Brossaud et al. (50) has provided, for the first time, important clues on the usefulness of urinary steroid profiling with GC/MS in improving the precision of the functional diagnosis of adrenal incidentalomas. Finally, further studies are also needed to understand the optimal treatment for patients with SH, according to their secreting pattern and to the related co-morbidities. To date, there are three ongoing trials investigating the outcome of surgery vs medical treatment in a randomized-controlled setting (available at https://www.clinicaltrials.gov/). Among these, a randomized-controlled trial has been recently designed on a Europe-wide basis in the context of the European Network for the Study of the Adrenal Tumors (ENS@T): Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas (CHIRACIC) (trial registration number NCT02364089). The results of this trial, together with the others, are expected to provide extremely useful information on the pathogenetic link between cortisol and cardiovascular diseases, which will help in the identification of a subgroup of patients with SH who will benefit from surgical treatment.

**Conclusion**

Considering all the data reviewed above, it is clear that patients with SH have an increased rate of co-morbidities, such as hypertension, impaired glucose metabolism and increased visceral fat. Albeit the cause-effect relationship with cortisol hypersecretion is difficult to clearly highlight due to the cross-sectional design of the majority of the studies, patients with SH are at an increased cardiovascular risk with respect to their non-functioning counterparts. Consequently, patients with SH are more prone to incur cardiovascular diseases and related mortality in a long-term run. In this context, cortisol per se seems to be an important determining factor. Considering that those patients are exposed to mild cortisol levels for a long period, mainly because of the incidental diagnosis and the observational follow-up strategy performed in several centers, a better characterization of the patients is highly needed in order to identify those who can benefit from surgical treatment vs intensive medical therapy of co-morbidities. In conclusion, in the author’s opinion, SH should be considered a disease with serious implications on the metabolic and cardiovascular systems.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

**Funding**

M Reincke is supported by a grant of the Else Kröner-Fresenius Stiftung (2012_A103) in support of the German Cushing’s registry (CUSTODES).

**Acknowledgements**

This paper forms part of a special issue of European Journal of Endocrinology on Cushing’s syndrome. This article is adapted from work presented at the IMPROCUSH-1: Improving Outcome of Cushing’s Syndrome symposium, 12–14 October 2014. The meeting was supported by the European Science Foundation, Deutsche Forschungsgemeinschaft, Carl Friedrich von Siemens Stiftung, European Neuroendocrine Association and the Deutsche Gesellschaft für Endokrinologie. The opinions or views expressed in this article are those of the authors, and do not necessarily reflect the opinions or recommendations of the European Science Foundation.
References


68 Kim BY, Chun AR, Kim KJ, Jung CH, Kang SK, Mok JO & Kim CH. Clinical characteristics and metabolic features of patients with adrenal incidentalomas with or without subclinical Cushing’s syndrome. Endocrinology and Metabolism 2014 29 457–463. (doi:10.3803/EnM.2014.29.4.457)